| http://dbpedia.org/ontology/abstract
|
リッジバック・バイオセラピューティクス（英語: Ridgeback Biotherapeutics）は、マイアミに拠点を置くバイオテクノロジーの企業である。
, 里奇巴克（Ridgeback Biotherapeutics）是一家总部位于美國迈阿 … 里奇巴克（Ridgeback Biotherapeutics）是一家总部位于美國迈阿密的生物技术公司，主要参与开发2019冠状病毒病疫情药物。 里奇巴克由对冲基金经理兼医生Wayne Holman（前 ）和他的妻子Wendy Holman拥有。 Wendy是该公司的首席执行官，该公司称自己为。 2020年初，里奇巴克从埃默里大學购买了莫納皮拉韋商业开发的独家许可，该药物最初是由包括國家衛生院在内的美國联邦机构提供的1600万美元开发的。該交易的条款没有披露。瑞克·布萊特表示，里奇巴克曾經游说政府提供数百万美元的资金来帮助开发莫納皮拉韋。 默克藥廠与里奇巴克合作進行莫納皮拉韋人体临床试验。里奇巴克还开发了许多其他药物，例如针对埃博拉病毒的单克隆抗体Ansuvimab。验。里奇巴克还开发了许多其他药物，例如针对埃博拉病毒的单克隆抗体Ansuvimab。
, Ridgeback Biotherapeutics is a Miami based … Ridgeback Biotherapeutics is a Miami based biotechnology company, primarily known for their involvement in developing a successful COVID-19 medication. Ridgeback is privately owned by hedge fund manager and physician, Wayne Holman (formerly of S.A.C. Capital Advisors) and his wife Wendy Holman. Wendy is the CEO at the company, which refers to itself as a majority woman owned business. In early 2020 Ridgeback purchased an exclusive license for the commercial development of Molnupiravir from Emory University, where the drug was initially developed with $16 million in grants from Federal agencies including the National Institutes of Health. The terms of the deal were undisclosed. Molnupiravir was initially researched as a treatment for influenza, but may have broad spectrum activity against other viruses. Ridgeback was mentioned in a whistleblower complaint from Rick Bright, former director of the Biomedical Advanced Research and Development Authority. The complaint alleged that Ridgeback lobbied the government for millions in funding to help develop Molnupiravir. Merck & Co. partnered with Ridgeback to perform clinical trials with Molnupiravir in humans to treat COVID-19. Ridgeback has also developed a number of other advanced medications such as monoclonal antibody Ansuvimab against the Ebola virus.ntibody Ansuvimab against the Ebola virus.
|
| http://dbpedia.org/ontology/wikiPageID
|
69214076
|
| http://dbpedia.org/ontology/wikiPageLength
|
5722
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1105344118
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Broad-spectrum_antiviral_drug +
, http://dbpedia.org/resource/National_Institutes_of_Health +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Merck_&_Co. +
, http://dbpedia.org/resource/Molnupiravir +
, http://dbpedia.org/resource/Miami%2C_Florida +
, http://dbpedia.org/resource/Woman-owned_business +
, http://dbpedia.org/resource/Influenza +
, http://dbpedia.org/resource/Category:Health_care_companies_based_in_Florida +
, http://dbpedia.org/resource/COVID-19 +
, http://dbpedia.org/resource/Biomedical_Advanced_Research_and_Development_Authority +
, http://dbpedia.org/resource/Emory_University +
, http://dbpedia.org/resource/S.A.C._Capital_Advisors +
, http://dbpedia.org/resource/Rick_Bright +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Med-company-stub +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Health_care_companies_based_in_Florida +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Ridgeback_Biotherapeutics?oldid=1105344118&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Ridgeback_Biotherapeutics +
|
| owl:sameAs |
https://global.dbpedia.org/id/G7iFe +
, http://zh.dbpedia.org/resource/%E9%87%8C%E5%A5%87%E5%B7%B4%E5%85%8B +
, http://dbpedia.org/resource/Ridgeback_Biotherapeutics +
, http://www.wikidata.org/entity/Q109546866 +
, http://ja.dbpedia.org/resource/%E3%83%AA%E3%83%83%E3%82%B8%E3%83%90%E3%83%83%E3%82%AF%E3%83%BB%E3%83%90%E3%82%A4%E3%82%AA%E3%82%BB%E3%83%A9%E3%83%94%E3%83%A5%E3%83%BC%E3%83%86%E3%82%A3%E3%82%AF%E3%82%B9 +
|
| rdfs:comment |
里奇巴克（Ridgeback Biotherapeutics）是一家总部位于美國迈阿 … 里奇巴克（Ridgeback Biotherapeutics）是一家总部位于美國迈阿密的生物技术公司，主要参与开发2019冠状病毒病疫情药物。 里奇巴克由对冲基金经理兼医生Wayne Holman（前 ）和他的妻子Wendy Holman拥有。 Wendy是该公司的首席执行官，该公司称自己为。 2020年初，里奇巴克从埃默里大學购买了莫納皮拉韋商业开发的独家许可，该药物最初是由包括國家衛生院在内的美國联邦机构提供的1600万美元开发的。該交易的条款没有披露。瑞克·布萊特表示，里奇巴克曾經游说政府提供数百万美元的资金来帮助开发莫納皮拉韋。 默克藥廠与里奇巴克合作進行莫納皮拉韋人体临床试验。里奇巴克还开发了许多其他药物，例如针对埃博拉病毒的单克隆抗体Ansuvimab。验。里奇巴克还开发了许多其他药物，例如针对埃博拉病毒的单克隆抗体Ansuvimab。
, リッジバック・バイオセラピューティクス（英語: Ridgeback Biotherapeutics）は、マイアミに拠点を置くバイオテクノロジーの企業である。
, Ridgeback Biotherapeutics is a Miami based … Ridgeback Biotherapeutics is a Miami based biotechnology company, primarily known for their involvement in developing a successful COVID-19 medication. Ridgeback is privately owned by hedge fund manager and physician, Wayne Holman (formerly of S.A.C. Capital Advisors) and his wife Wendy Holman. Wendy is the CEO at the company, which refers to itself as a majority woman owned business.itself as a majority woman owned business.
|
| rdfs:label |
Ridgeback Biotherapeutics
, 里奇巴克
, リッジバック・バイオセラピューティクス
|
